First‐in‐Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure | Zendy

Vardeny O | Zendy; Tacheny T | Zendy; Solomon S D | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

First‐in‐Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure

Author(s) -

Vardeny O,

Tacheny T,

Solomon S D

Publication year - 2013

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2013.146

Subject(s) - neprilysin , sacubitril , valsartan , heart failure , natriuretic peptide , ejection fraction , pharmacology , angiotensin ii , angiotensin receptor , medicine , npr2 , clinical pharmacology , chemistry , receptor , blood pressure , biochemistry , enzyme

Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B‐type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning. Clinical Pharmacology & Therapeutics (2013); 94 4, 445–448. doi: 10.1038/clpt.2013.146

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research